| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,700 | 6,850 | 13:06 | |
| 6,750 | 6,800 | 12:23 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | INSILICO Nominates Next-Generation Small Molecule GIPR Antagonist | 2 | AASTOCKS | ||
| Mi | INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE NOMINATES NEXT-GENERATION SMALL MOLECULE GIPR ANTAGONIST FOR POTENTIAL INTERVENTION OF OBESITY ... | 4 | HKEx | ||
| 24.09. | Jefferies: INSILICO Has Strong Business Development Momentum, Drug Assets More Important Than Proprietary Models | 5 | AASTOCKS | ||
| 21.09. | Insilico Jumps After Signing Deal to Develop Biology AI Models Worth Tens of Millions of US Dollars | 6 | Yicai Global | ||
| 21.09. | JPM: INSILICO Longevity Research Broadens AIDD Platform Applications; Maintains Overweight Rating | 17 | AASTOCKS | ||
| 21.09. | INSILICO Reaches AI Joint Development Partnership With Contract Value Up to Tens of Millions of USD | 2 | AASTOCKS | ||
| INSILICO MEDICINE Aktie jetzt für 0€ handeln | |||||
| 21.09. | INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE ENTERED INTO AN AI CO-DEVELOPMENT COLLABORATION WITH A CONTRACT VALUE UP TO TENS OF MILLIONS ... | 3 | HKEx | ||
| 18.09. | Insilico Medicine's Alex Zhavoronkov bets China and AI can deliver the drug industry's next breakthrough | 6 | Fortune | ||
| 18.09. | Daiwa: INSILICO BD and PCC Output Hit Record High | 8 | AASTOCKS | ||
| 14.09. | Insilico Medicine's Rentosertib Shows Potential Biological Age Reversal Across Six Proteomic Aging Clocks | 2 | pulse2.com | ||
| 14.09. | INSILICO Chairman Increases Stake by 113,500 Shares | 5 | AASTOCKS | ||
| 14.09. | INSILICO (03696): VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY CHAIRMAN OF THE BOARD | 1 | HKEx | ||
| 10.09. | INSILICO Completes First Patient Enrollment and Dosing in Phase III Clinical Trial of Rentosertib for Idiopathic Pulmonary Fibrosis | 5 | AASTOCKS | ||
| 10.09. | Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug | 668 | PR Newswire | CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today... ► Artikel lesen | |
| 10.09. | INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE COMPLETED FIRST PATIENT ENROLLMENT AND DOSING IN PHASE III (GENESIS-IPF-3) CLINICAL TRIAL OF ... | 1 | HKEx | ||
| 09.09. | Insilico's co-CEO hopes 'we might have a chance to stop biological aging' after promising results from its fibrosis drug trial | 2 | Fortune | ||
| 09.09. | Citi: New Biomarker Evidence for INSILICO 's Rentosertib Supports Potential Anti-aging Effects | 18 | AASTOCKS | ||
| 08.09. | KI-Pharmasparte: Citi kürt Insilico zum Top-Pick in China | 7 | Investing.com Deutsch | ||
| 08.09. | INSILICO Once Surges ~10% on Strategic Co-op Deal with Mozhuo Biotech | 3 | AASTOCKS | ||
| 04.09. | INSILICO (03696): VOLUNTARY ANNOUNCEMENT SHARE INCREASING PLAN BY THE CHAIRMAN OF THE BOARD | 5 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 44,325 | +1,05 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius vor einem Treffen mit dem Chef Michael Sen auf "Buy" mit einem Kursziel von 55 Euro belassen. Die geschäftliche... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,550 | +0,75 % | FMC, MustGrow Biologics, Corteva - Diese Technologie verändert den Acker | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics. Die Landwirtschaft steht unter enormem Innovationsdruck. Schädlinge entwickeln Resistenzen, extreme Wetterereignisse bedrohen Ernten und... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 37,990 | +1,44 % | ROUNDUP/Aktien Frankfurt Eröffnung: Leicht im Minus - Sorgen in Europa bleiben | FRANKFURT (dpa-AFX) - Zum Auftakt der neuen Börsenwoche haben sich am deutschen Aktienmarkt zunächst keine größeren Sprünge abgezeichnet. Der Dax hielt sich im frühen Handel über der runden Marke von... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 31,320 | +2,89 % | Aktien Frankfurt Ausblick: Ruhiger Wochenauftakt erwartet - Dax stabil | FRANKFURT (dpa-AFX) - Zum Auftakt der neuen Börsenwoche zeichnen sich am deutschen Aktienmarkt zunächst keine größeren Kursbewegungen ab. Der X-Dax signalisierte eine Stunde vor Handelsbeginn ein Plus... ► Artikel lesen | |
| INTUITIVE SURGICAL | 362,65 | +0,12 % | Intuitive Surgical: Bewertungsabschlag ohne Bruch der Investment-Story - Chance für geduldige Qualitätsanleger? | Intuitive Surgical bleibt operativ auf Kurs, während die Bewertung nachgibt. Trotz temporärer Belastungen durch Nachholeffekte aus der Pandemie und makroökonomische Unsicherheiten sieht Seeking Alpha... ► Artikel lesen | |
| UNITEDHEALTH | 338,20 | +0,24 % | UnitedHealthcare Unveils FY27 Medicare Advantage Plans | MINNETONKA (dpa-AFX) - Health care and well-being major UnitedHealth Group Inc. (UNH) Thursday introduced its 2027 Medicare Advantage plans, focused on affordability, simplicity and a more connected... ► Artikel lesen | |
| MEDTRONIC | 77,78 | -0,84 % | Medtronic Announces Regulatory Milestones For Cardiac Mapping Software | WASHINGTON (dpa-AFX) - Wednesday, Medtronic plc (MDT) said it received FDA clearance and CE Mark for the latest Affera Prism-2 Mapping Software and CE Mark for the PulseSelect ProxBox Adapter... ► Artikel lesen | |
| GERRESHEIMER | 29,060 | +2,32 % | DAX wenig bewegt - BASF, Evonik, Gerresheimer, VW: Was Anleger wissen müssen Video | Markus Königer, Market Making Derivatives Products der ICF BANK AG, fasst die vergangene Handelswoche zusammen. Der DAX präsentiert sich wenig bewegt, was angesichts der hohen Inflation und dem volatile... ► Artikel lesen | |
| THERMO FISHER | 602,40 | -0,10 % | Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis | TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company focused on developing innovative therapies and technologies... ► Artikel lesen | |
| TELADOC HEALTH | 5,230 | +1,44 % | Teladoc Health, Inc.: Teladoc Health Announces Chief Legal Officer Transition | NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced a leadership transition in its legal function. After 11 years with... ► Artikel lesen | |
| STRATEC | 21,850 | +1,63 % | EQS-PVR: STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: STRATEC SE
STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| ESSILORLUXOTTICA | 146,10 | +1,42 % | Mehr als 100 KI-Brillenvarianten: Was Meta und EssilorLuxottica für die Optikbranche verändern | ||
| BRIGHTSPRING HEALTH SERVICES | 62,03 | +0,05 % | BMO Capital reiterates Outperform on BrightSpring Health stock | ||
| LIFESTANCE HEALTH GROUP | 12,220 | 0,00 % | KeyBanc raises Lifestance Health stock price target on specialty care growth | ||
| HEARTFLOW | 52,24 | +0,06 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen |